Profile of saxagliptin in the treatment of type 2 diabetes: focus on Japanese patients

Saxagliptin is a selective and potent dipeptidyl peptidase (DPP)-4 inhibitor, approved as an adjunct to diet and exercise to improve glycemic control in type 2 diabetes mellitus (T2DM) in the USA on July 2009, and had been launched globally in over 86 countries by September 2013. In patients with T2...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Konya, Hiroyuki, Yano, Yuzo, Matsutani, Satoshi, Tsunoda, Taku, Ikawa, Takashi, Kusunoki, Yoshiki, Matsuo, Toshihiro, Miuchi, Masayuki, Katsuno, Tomoyuki, Hamaguchi, Tomoya, Miyagawa, Jun-ichiro, Namba, Mitsuyoshi
Médium: Artigo
Jazyk:Inglês
Vydáno: Dove Medical Press 2014
Témata:
Review
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4103926/
https://ncbi.nlm.nih.gov/pubmed/25050065
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/TCRM.S46076
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky